ppt Viral Hepatitis Flashcards
ombitasvir
NS5A inhibitor
paritaprevir
NS3/4A protease inhibitor
dasabuvir
NS5B polymerase inhibitor
oral telaprevir or boceprevir
NS3/4A protease inhibitors
Source of virus
fecal oral
Hep A
Hep E
Source of virus
Blood Born/ Body fluids
Hep B
Hep C
Hep D
Route of transmission
percutaneous
permucosal
Hep B
Hep C
Hep D
Source of virus
Hep B
Hep C
Hep D
Blood Born/ Body fluids
Source of virus
Hep A
Hep E
Fecal Oral
Route of transmission
Hep B
Hep C
Hep D
percutaneous
permucosal
Hep A prevention
Pre and Post exposure immunization
*Killed Vaccine (One serotype)
*Passive Vaccination w Abs
(not currently in US)
Hep B prevention
Pre and Post exposure immunization
Hep C prevention
Blood donor screening
modify risk behavior
Pre and Post exposure immunization
Hep A
Hep B
Hep D
Hep E prevention
Immunize
Safe drinking water
No FDA-approved vaccine, but proven HEV vaccine in China
Chronic Hep disease
B, C, D
Acute Hepatitis – Clinical Symptoms
Nausea, vomiting Abdominal pain Loss of appetite Fever Diarrhea Light (clay) colored stools Dark urine Jaundice (yellowing of eyes, skin)
Hep A ddx
Diagnosis: IgM anti-HAV
Hep A incubation
Average 30 days Range 15-50 days
Fulminant hepatitis in pregnant women (3rd Trimester)!
~______% mortality.
20 %
Hep E
Surface Antigen Vaccine
(One serotype)
Hepadnavirus
Hep B
Neutralizing Abs to Surface Antigen Protective (anti-HBsAg)
Mother to infant (perinatal) transmission –> chronic infection of infant. Infection of infant prevented if vaccination ______ at birth.
immediately
Hep B incubation
Average 60-90 days
Range 45-180 days
Circular ssRNA encoding delta antigen
Particles packaged with HBV S antigen (HBVsAg)
Hep D
HDV becomes chronic…..persists along with HBV.
Acute infections usually subclinical50% to 80% of acute infections –>Chronic Infections
Hep C
NS3 Protease. (______________).
NS5A. Targeted by ledipasvir & ombitasvir.
NS5B. Targeted by sofosbuvir & dasabuvir.
telaprevir & boceprevir & paritaprevir
HEP C
HEP C incubation
Average 6-7 weeks
Range 2-26 weeks
HAV
anti-HAV IgM –> recent infection
Anti-HAV IgG –> past infection or vaccine (lifelong immunity)
x
NS3 Protease. (telaprevir & boceprevir & paritaprevir).
NS5A. Targeted by ____________
NS5B. Targeted by sofosbuvir & dasabuvir.
ledipasvir & ombitasvir.
HEP C
HAV
anti-HAV IgM –> recent infection
Anti-HAV IgG –> ___________
past infection or vaccine (lifelong immunity)
HBV
HBsAg –> Infectious (ongoing infection)
Anti-HBsAg –> ______________
past infection or vaccine (lifelong immunity)
NS3 Protease. (_______________).
NS5A. Targeted by ledipasvir & ombitasvir.
NS5B. Targeted by sofosbuvir & dasabuvir.
telaprevir & boceprevir & paritaprevir
HEP C
HBV
HBsAg –> I__________
Anti-HBsAg –> past infection or vaccine (lifelong immunity)
infectious (ongoing infection)
HCV
HCV antibodies________________
HCV RNA (RT-PCR) –> Ongoing infection
(previous or ongoing infection)
HDV
HDV ∆Ag –> ongoing infection
HDV RNA –> ______________
ongoing infection
HCV HCV antibodies (previous or ongoing infection) HCV RNA (RT-PCR) --> \_\_\_\_\_\_\_\_\_\_\_\_\_\_
Ongoing infection
HEV ddx
anti-HEV IgM
RT-PCR RNA from stool
